Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents

Clicks: 379
ID: 272363
2016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #2 of 3 articles by views in Hepatology (Baltimore, Md.)

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
SVR12 rates for sofosbuvir-based DAA regimens in HCV-MCS were 83%, significantly higher than historical controls treated with pegylated interferon and ribavirin; patients with glomerulonephritis experienced improvement in renal function, including those not concomitantly treated with immunosuppressi …
Reference Key
me2016hepatologytreatment Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sise ME;Bloom AK;Wisocky J;Lin MV;Gustafson JL;Lundquist AL;Steele D;Thiim M;Williams WW;Hashemi N;Kim AY;Thadhani R;Chung RT;;
Journal Hepatology (Baltimore, Md.)
Year 2016
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.